Page 210 - Read Online

Galletti et al. Using CTCs in prostate cancer

DECLARATIONS therapy in prostate cancer (STAMPEDE): survival results from an
adaptive, multiarm, multistage, platform randomised controlled trial.
Authors’ contributions Lancet 2016;387:1163-77.
Concept and design: G. Galletti, D. Worroll, D.M. 5. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD,
Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson
Nanus, P. Giannakakou D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker
Literature search: G. Galletti, D. Worroll CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle
Manuscript preparation: G. Galletti, D. Worroll AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E,
Manuscript editing and review: G. Galletti, D. Worroll, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail
D.M. Nanus, P. Giannakakou N, Money-Kyrle J, O’Sullivan J, Parikh O, Protheroe A, Robinson
A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar
Financial support and sponsorship MKB, Sydes MR, STAMPEDE Investigators. Abiraterone for prostate
cancer not previously treated with hormone therapy. N Engl J Med
This work was partially supported by the Clinical 2017;377:338-51.
and Translational Science Center at Weill Cornell 6. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A,
NIH/NCATS grant ULTR00457 (to GG), the NIH Alekseev BY, Ozguroglu M, Ye D, Feyerabend S, Protheroe A,
T32 Training grant 5T32CA062948-22 (to GG), by De Porre P, Kheoh T, Park YC, Todd MB, Chi KN, LATITUDE
the National Institutes of Health (NIH) Grants R01 Investigators. Abiraterone plus prednisone in metastatic, castration-
CA137020 (to PG) and R01 CA179100 (to PG). sensitive prostate cancer. N Engl J Med 2017;377:352-60.
7. Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P,
Conflicts of interest Nanus DM. Circulating tumor cells in prostate cancer diagnosis
and monitoring: an appraisal of clinical potential. Mol Diagn Ther
There are no conflicts of interest. 2014;18:389-402.
8. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell
Patient consent research. Nat Rev Cancer 2014;14:623-31.
Not applicable. 9. Pantel K, Alix-Panabieres C. Detection methods of circulating tumor
cells. J Thorac Dis 2012;4:446-7.
Ethics approval 10. Miyamoto DT, Lee RJ. Cell-free and circulating tumor cell-based
Not applicable. biomarkers in men with metastatic prostate cancer: tools for real-time
precision medicine? Urol Oncol 2016;34:490-501.
11. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax
REFERENCES S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Hofler G, Eisner
F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl
1. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, JB, Speicher MR. Complex tumor genomes inferred from single
Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen circulating tumor cells by array-CGH and next-generation sequencing.
DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Cancer Res 2013;73:2965-75.
Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzen L, Coleman 12. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg
R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R,
J, Shan M, Bruland OS, Sartor O, Investigators A. Alpha emitter Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel
radium-223 and survival in metastatic prostate cancer. N Engl J Med B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM,
2013;369:213-23. Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME,
2. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW,
Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis Golub TR, Getz G, Boehm JS, Love JC. Whole-exome sequencing
ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura of circulating tumor cells provides a window into metastatic prostate
G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo cancer. Nat Biotechnol 2014;32:479-84.
F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, 13. Millner LM, Linder MW, Valdes R Jr. Circulating tumor cells: a
Investigators P. Enzalutamide in metastatic prostate cancer before review of present methods and the need to identify heterogeneous
chemotherapy. N Engl J Med 2014;371:424-33. phenotypes. Ann Clin Lab Sci 2013;43:295-304.
3. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger 14. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-
M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang like cells. J Clin Invest 2009;119:1417-9.
NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. 15. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal
Chemohormonal therapy in metastatic hormone-sensitive prostate transition. J Clin Invest 2009;119:1420-8.
cancer. N Engl J Med 2015;373:737-46. 16. Harouaka R, Kang Z, Zheng SY, Cao L. Circulating tumor cells:
4. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, advances in isolation and analysis, and challenges for clinical
Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, applications. Pharmacol Ther 2014;141:209-21.
Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, 17. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M,
Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn
P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti
Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid
O’Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, biopsy in patients with metastatic prostate, pancreatic and breast
Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, cancers. Phys Biol 2012;9:016003.
Wagstaff J, Parmar MK, STAMPEDE investigators. Addition of 18. Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L,
docetaxel, zoledronic acid, or both to first-line long-term hormone Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel
202 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ September 27, 2017